查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930094

全球mRNA疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

mRNA Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 请询问到货日

价格

mRNA疫苗市场成长驱动因子

全球mRNA疫苗市场正在迅速改变製药和生物技术产业，其动力来自技术创新、强劲的研发投入以及除新冠肺炎以外的治疗应用拓展。根据财富商业洞察（Fortune Business Insights）预测，该市场规模预计将在2025年达到60.1亿美元，从2026年的68.5亿美元增长到2034年的256.4亿美元，预测期内复合年增长率（CAGR）高达17.94%。 2025年，北美市场将以31.47%的市占率领先，这得益于其先进的医疗基础设施和积极的研发活动。

市场概览

信使RNA (mRNA) 疫苗透过诱导细胞产生蛋白质来触发免疫反应。与传统疫苗不同，mRNA平台具有开发速度快、灵活性高和可扩展生产等优势。 COVID-19 mRNA疫苗的成功推出标誌着市场的一个转捩点，展现了该技术在包括传染病、自体免疫疾病和肿瘤在内的多种疾病领域的潜力。

人工智慧 (AI) 工具在疫苗开发和临床试验中的应用等技术进步正在进一步加速创新。包括Moderna Inc.、辉瑞公司、BioNTech、CureVac SE和葛兰素史克公司在内的主要公司正在大力投资研发，以拓展其mRNA疫苗产品线。

市场亮点

  • 市场规模（2025年）：60.1亿美元
  • 市场规模（2026年）：68.5亿美元
  • 市场规模（2034年）：256.4亿美元
  • 复合年增长率（2026-2034年）：17.94%

市场快速成长反映了在新冠疫情期间mRNA技术在全球展现其优势后，人们对该技术的信心日益增强。

市场驱动因素

推动市场成长的主要因素是针对mRNA疫苗的研发活动不断增加。新冠疫苗的成功促使製药公司和各国政府探索利用mRNA平台开发流感、呼吸道合胞病毒（RSV）、爱滋病毒（HIV）和其他传染病疫苗。公共和私营部门的投资持续增加，以支持创新。

例如，Moderna 已宣布计划在 2024 年至 2028 年间投资约 250 亿美元用于研发，以扩大其 mRNA 药物产品组合。此外，辉瑞的智慧数据查询 (SDQ) 等人工智慧工具正在提高临床试验效率，缩短研发週期，并有助于加快产品上市速度。

市场限制因素与挑战

儘管成长前景强劲，但由于监管环境严格，市场仍面临挑战。除紧急情况外，mRNA 疫苗的监管审批流程复杂，包括提交研究性新药申请 (IND) 和生物製品许可申请 (BLA)，这可能会延迟商业化进程。生产製造的复杂性、冷链储存要求以及大规模生产的限制也阻碍了市场成长，尤其是在资源匮乏的地区。

另一个主要挑战是由于错误讯息和安全担忧而导致的疫苗犹豫。疫苗接受度的区域差异可能会限制加强剂和新研发的mRNA疫苗的广泛应用。

市场机会

mRNA疫苗在新冠肺炎以外的应用拓展带来了巨大的成长机会。目前，针对呼吸道合胞病毒（RSV）、流感、疟疾和自体免疫疾病的多种候选疫苗正处于临床开发阶段。 mRNA平台的灵活性使其能够快速适应新出现的病原体，这使其在未来应对大流行病方面具有极高的价值。

此外，製药公司与国际卫生组织之间日益紧密的合作正在加速创新。例如，BioNTech与流行病防范创新联盟（CEPI）在被忽视疾病领域的合作，凸显了mRNA技术应用范围的不断扩大。

细分市场考量

依类型划分，新冠肺炎疫苗作为首批获批的mRNA疫苗产品，占了市场主导地位。然而，在不断扩充的研发管线支持下，非新冠疫苗预计将快速成长。以适应症划分，新冠病毒感染疫苗占主导地位，但呼吸道合胞病毒（RSV）疫苗在近期获得监管部门批准后，展现出强劲的未来潜力。依分销管道划分，医院和零售药局占了相当大的占有率，这得益于政府的疫苗接种计划。

区域展望

北美市场凭藉强大的研发基础设施和政府投资，预计将引领市场，2025年达到18.9亿美元，2026年达到22.8亿美元。欧洲市场在有利的政策和研究机构的支持下位居第二。亚太地区预计将实现显着增长，这得益于传染病的日益流行、临床试验的扩大以及生物技术投资的增加。世界其他地区（ROW）由于疫苗可及性改善和区域生产扩张，正保持稳定成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要公司新产品发布
  • 主要公司产品线分析
  • mRNA疫苗市场技术进步
  • 主要疾病发生率/盛行率（2025年）
  • 关键产业趋势（併购、合作等）

第五章：全球mRNA疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • COVID-19疫苗
    • 非COVID-19疫苗
  • 市场分析、洞察与预测：依适应症划分
    • COVID-19感染
    • 呼吸道合胞病毒（RSV）感染
    • 其他
  • 市场分析、洞察与预测：依销售管道划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 世界其他地区（ROW）

第六章 北美mRNA疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲mRNA疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区mRNA疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：世界其他地区 (ROW) mRNA 疫苗市场分析：洞察与预测（2021-2034）

第十章：竞争分析

  • 全球市占率分析（2025）
  • 公司简介
  • Moderna Inc.
  • BioNTech
  • CureVac SE
  • GSK plc
  • Sanofi
  • Pfizer Inc.
  • Gennova Biopharmaceuticals Limited
  • Walvax Biotechnology有限公司
  • Arcturus Therapeutics
Product Code: FBI113546

Growth Factors of mRNA vaccines Market

The global mRNA vaccines market is rapidly transforming the pharmaceutical and biotechnology landscape, supported by technological innovation, strong research investments, and expanding therapeutic applications beyond COVID-19. According to Fortune Business Insights, the market was valued at USD 6.01 billion in 2025 and is projected to grow from USD 6.85 billion in 2026 to USD 25.64 billion by 2034, registering a strong CAGR of 17.94% during the forecast period. In 2025, North America dominated the market with a 31.47% share, driven by advanced healthcare infrastructure and strong R&D activity.

Market Overview

mRNA (messenger RNA) vaccines work by instructing cells to produce proteins that trigger an immune response. Unlike traditional vaccines, mRNA platforms enable faster development, higher flexibility, and scalable manufacturing. The successful deployment of COVID-19 mRNA vaccines marked a turning point for the market and validated the technology's potential across multiple disease areas, including infectious diseases, autoimmune disorders, and oncology.

Technological advancements, including the integration of artificial intelligence (AI) tools in vaccine development and clinical trials, have further accelerated innovation. Key players such as Moderna Inc., Pfizer Inc., BioNTech, CureVac SE, and GSK plc are heavily investing in research to expand their mRNA vaccine pipelines.

Market Size Highlights

  • 2025 Market Size: USD 6.01 billion
  • 2026 Market Size: USD 6.85 billion
  • 2034 Market Size: USD 25.64 billion
  • CAGR (2026-2034): 17.94%

The market's rapid growth reflects increasing confidence in mRNA technology following its global validation during the COVID-19 pandemic.

Market Drivers

A major driver of market growth is the increase in R&D activities focused on mRNA-based vaccines. The success of COVID-19 vaccines has encouraged pharmaceutical companies and governments to explore mRNA platforms for influenza, RSV, HIV, and other infectious diseases. Public and private sector investments continue to rise to support innovation.

For instance, Moderna announced plans to invest approximately USD 25 billion in R&D from 2024 to 2028, aimed at expanding its mRNA medicine portfolio. Additionally, AI-powered tools, such as Pfizer's Smart Data Query (SDQ), have improved clinical trial efficiency, reducing development timelines and supporting faster market entry.

Market Restraints and Challenges

Despite strong growth prospects, the market faces challenges from a stringent regulatory landscape. Regulatory approval for mRNA vaccines outside emergency scenarios involves complex processes, including IND and BLA submissions, which may delay commercialization. Manufacturing complexities, cold-chain storage requirements, and large-scale production constraints also hinder growth, especially in low-resource regions.

Another key challenge is vaccine hesitancy, driven by misinformation and safety concerns. Variations in vaccine acceptance across regions can limit uptake, particularly for booster doses and newly developed mRNA vaccines.

Market Opportunities

The expanding applications of mRNA vaccines beyond COVID-19 present significant growth opportunities. Several candidates targeting RSV, influenza, malaria, and autoimmune diseases are currently in the clinical pipeline. The flexibility of mRNA platforms allows rapid adaptation to emerging pathogens, making them highly valuable for future pandemic preparedness.

Additionally, increasing collaborations between pharmaceutical companies and global health organizations are accelerating innovation. Partnerships such as BioNTech's collaboration with CEPI for neglected diseases highlight the growing scope of mRNA technology.

Segmentation Insights

By type, COVID-19 vaccines dominated the market, as they were the first approved mRNA-based products. However, non-COVID-19 vaccines are expected to grow rapidly, supported by pipeline expansion. By indication, COVID-19 infection held the dominant share, while RSV vaccines show strong future potential following recent regulatory approvals. By distribution channel, hospital and retail pharmacies accounted for a significant share, supported by government vaccination programs.

Regional Outlook

North America led the market, with a valuation of USD 1.89 billion in 2025 and USD 2.28 billion in 2026, driven by strong R&D infrastructure and government investments. Europe ranked second, supported by favorable policies and research institutions. Asia Pacific is expected to grow substantially, fueled by rising infectious disease prevalence, increasing clinical trials, and expanding biotechnology investments. The rest of the world is witnessing steady growth due to improved access initiatives and regional manufacturing expansions.

Competitive Landscape

The market is highly concentrated, with Pfizer Inc., Moderna Inc., and BioNTech holding significant shares. These companies continue to strengthen their positions through product innovation, strategic collaborations, and pipeline expansion. Other notable players include CureVac SE, GSK plc, Sanofi, and Arcturus Therapeutics.

Conclusion

In conclusion, the global mRNA vaccines market is poised for robust and sustained growth, expanding from USD 6.01 billion in 2025 to USD 25.64 billion by 2034. Continuous R&D investments, technological advancements, and expanding therapeutic applications are driving market momentum. While regulatory complexities and vaccine hesitancy pose challenges, the proven success and adaptability of mRNA technology position it as a cornerstone of future vaccine development worldwide.

Segmentation By Type

  • COVID-19 Vaccines
  • Non-COVID-19 Vaccines

By Indication

  • COVID-19 Infection
  • Respiratory Syncytial Virus (RSV) Infection
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Indication, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Indication, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Rest of the World (By Type, Indication, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. New Product Launches, By Key Players
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Technological Advancements in the mRNA Vaccines Market
  • 4.4. Incidence/Prevalence of Key Diseases, 2025
  • 4.5. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)

5. Global mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. COVID-19 Vaccines
    • 5.1.2. Non-COVID-19 Vaccines
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. COVID-19 Infection
    • 5.2.2. Respiratory syncytial virus (RSV) Infection
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. COVID-19 Vaccines
    • 6.1.2. Non-COVID-19 Vaccines
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. COVID-19 Infection
    • 6.2.2. Respiratory syncytial virus (RSV) Infection
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. COVID-19 Vaccines
    • 7.1.2. Non-COVID-19 Vaccines
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. COVID-19 Infection
    • 7.2.2. Respiratory syncytial virus (RSV) Infection
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. COVID-19 Vaccines
    • 8.1.2. Non-COVID-19 Vaccines
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. COVID-19 Infection
    • 8.2.2. Respiratory syncytial virus (RSV) Infection
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. COVID-19 Vaccines
    • 9.1.2. Non-COVID-19 Vaccines
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. COVID-19 Infection
    • 9.2.2. Respiratory syncytial virus (RSV) Infection
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 10.2.1. Moderna Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. BioNTech
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. CureVac SE
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. GSK plc
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Sanofi
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Pfizer Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Gennova Biopharmaceuticals Limited
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Walvax Biotechnology Co., Ltd.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Arcturus Therapeutics
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 3: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 7: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America mRNA Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 11: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 15: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034a

List of Figures

  • Figure 1: Global mRNA Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global mRNA Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global mRNA Vaccines Market Value Share (%), by Indication, 2025 & 2034
  • Figure 4: Global mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global mRNA Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America mRNA Vaccines Market Value Share (%), by Type, 2025
  • Figure 8: North America mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 9: North America mRNA Vaccines Market Value Share (%), by Indication, 2025
  • Figure 10: North America mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America mRNA Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America mRNA Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe mRNA Vaccines Market Value Share (%), by Type, 2025
  • Figure 16: Europe mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 17: Europe mRNA Vaccines Market Value Share (%), by Indication, 2025
  • Figure 18: Europe mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific mRNA Vaccines Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 25: Asia Pacific mRNA Vaccines Market Value Share (%), by Indication, 2025
  • Figure 26: Asia Pacific mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Rest of the World mRNA Vaccines Market Value Share (%), by Type, 2025
  • Figure 32: Rest of the World mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 33: Rest of the World mRNA Vaccines Market Value Share (%), by Indication, 2025
  • Figure 34: Rest of the World mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Rest of the World mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Global mRNA Vaccines Market Share (%), By Company, 2025